In collaboration with other faculty members in the Prostate Cancer Research Group, I have been conducting clinically based integrative research in men afflicted with prostate cancer since the early 1980s. My main areas of current interest and of previous accomplishments include the following:

• Studies into using serum PSA levels for the case finding and screening for prostate cancer.
• Studies of the characteristics and clinical correlations of several serum PSA assays.
• Phase I, II, and III studies of sustained release LHRH agonists and the anti-androgen bicalutamide.
• Neoadjuvant and adjuvant approaches for prostate cancer primary therapy.
• Prostate cancer prevention trials.
• Phase I, II, and III studies of new therapies for hormone refractory prostate cancer.
• Studies into the effectiveness of palliative interventions in prostate cancer.
• New approaches in men with micrometastatic prostate cancer.

• Ahmann FR, Citrin DL, DeHaan HA, Guinan P, Jordan VC, Kreis W, Scott M, Trump DL. Zoladex: a sustained release monthly LHRH analogue for the treatment of advanced prostate cancer. JCO 5:912-917, 1987.
• Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multi-center clinical trial of 6,630 men. J of Urology 151:1283-1290, 1994.
• Dalkin BL, Ahmann FR, Nagle R, Johnson CS. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J of Urology 155:1357-1360, 1996.

• Bruce Dalkin, M.D., Associate Professor of Surgery, Chief, Division of Urology.
• Ray Nagle, M.D., Ph.D., Professor of Pathology, Chief, Immunopathology.
• Evan Hersh, M.D., Professor of Medicine, Chief of Immunobiologic Research.